In the trial, Ceftaroline was compared with the current standard therapy in 100 patients at 24 study sites worldwide. The clinical cure rate was 96.8% for subjects treated with Ceftaroline and 88.9% for those treated with the standard therapy of vancomycin, with or without adjunctive aztreonam.
According to the company, Ceftaroline also demonstrated excellent activity against gram-positive and gram-negative organisms isolated from patients in the study, including 100% of MRSA isolates inhibited at 0.5 mg/L or less.
“We’re very pleased with these results,” said Dennis Podlesak, CEO of Cerexa. “Ceftaroline’s high cure rates and broad spectrum of coverage clearly validate its potential as a potent first-line therapy with the significant added benefit of minimizing the need for combination therapy.”